Related Experiment Video

Updated: Jun 25, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy

Roger Abounader1

  • 1Departments of Neurology and Microbiology, University of Virginia Health System, Charlottesville, VA 22908, USA. ra6u@virginia.edu

Expert Review of Anticancer Therapy
|February 6, 2009
PubMed

Insights

Loss of tumor suppressor PTEN and activated receptor tyrosine kinases (RTKs) drive brain tumor (glioma) malignancy. Targeting these pathways, including with mTOR inhibitors, may improve glioma treatment outcomes.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer genetics

Background:

  • Gliomas are aggressive primary brain tumors with poor prognosis.
  • Common molecular alterations include loss of PTEN tumor suppressor and activation of receptor tyrosine kinases (RTKs).
  • PTEN and RTK signaling pathways are intricately linked in cancer development.

Purpose of the Study:

  • To review the molecular and functional interactions between PTEN and RTK pathways in glioma.
  • To discuss the implications of these interactions for current and future glioma therapies.
  • To explore the therapeutic potential of combining RTK-targeted treatments with therapies addressing PTEN loss.

Main Methods:

  • Literature review of molecular and functional interactions between PTEN and RTK signaling.
  • Analysis of PTEN's role in counteracting PI3K activation and influencing MAPK pathways.
  • Examination of PTEN status in relation to RTK-targeted therapy outcomes.

Main Results:

  • PTEN loss significantly impacts RTK-driven signaling and contributes to glioma malignancy.
  • PTEN modulates PI3K/AKT and MAPK pathways, affecting cell growth and survival.
  • PTEN status is a critical determinant for the efficacy of RTK-targeted therapies.

Conclusions:

  • Understanding PTEN-RTK interactions is crucial for developing effective glioma treatments.
  • Combined therapeutic strategies, such as RTK inhibition plus mTOR inhibition, show promise.
  • Targeting PTEN loss in conjunction with RTK pathways may overcome therapeutic resistance and improve patient outcomes.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...